Zhang, Z.; Bao, Q.; Fu, Y.; Wen, J.; Li, M.; Liu, Z.; He, G.; Wang, B.; Shen, Y.; Zhang, W.
The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy. J. Clin. Med. 2023, 12, 325.
https://doi.org/10.3390/jcm12010325
AMA Style
Zhang Z, Bao Q, Fu Y, Wen J, Li M, Liu Z, He G, Wang B, Shen Y, Zhang W.
The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy. Journal of Clinical Medicine. 2023; 12(1):325.
https://doi.org/10.3390/jcm12010325
Chicago/Turabian Style
Zhang, Zhusheng, Qiyuan Bao, Yucheng Fu, Junxiang Wen, Meng Li, Zhuochao Liu, Guoyu He, Beichen Wang, Yuhui Shen, and Weibin Zhang.
2023. "The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy" Journal of Clinical Medicine 12, no. 1: 325.
https://doi.org/10.3390/jcm12010325
APA Style
Zhang, Z., Bao, Q., Fu, Y., Wen, J., Li, M., Liu, Z., He, G., Wang, B., Shen, Y., & Zhang, W.
(2023). The Outcome of Discontinuing Tyrosine Kinase Inhibitors in Advanced Sarcoma Following a Favorable Tumor Response to Antiangiogenics Therapy. Journal of Clinical Medicine, 12(1), 325.
https://doi.org/10.3390/jcm12010325